Asterias Biotherapeutics Inc (NYSEMKT:AST) insider Edward Wirth sold 3,415 shares of the firm’s stock in a transaction that occurred on Thursday, October 6th. The shares were sold at an average price of $4.12, for a total transaction of $14,069.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Edward Wirth also recently made the following trade(s):
- On Friday, September 9th, Edward Wirth sold 14,760 shares of Asterias Biotherapeutics stock. The shares were sold at an average price of $3.52, for a total transaction of $51,955.20.
Asterias Biotherapeutics (NYSEMKT:AST) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.07. The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $1.14 million.
Several equities analysts have commented on AST shares. FBR & Co reiterated a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday, September 14th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Asterias Biotherapeutics in a research note on Sunday, September 11th. Finally, Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Thursday, August 18th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $7.75.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AST. Sabby Management LLC purchased a new position in Asterias Biotherapeutics during the second quarter valued at about $741,000. BlackRock Fund Advisors increased its position in Asterias Biotherapeutics by 114.4% in the second quarter. BlackRock Fund Advisors now owns 586,720 shares of the company’s stock valued at $1,408,000 after buying an additional 313,067 shares during the period. BlackRock Investment Management LLC increased its position in Asterias Biotherapeutics by 100.7% in the second quarter. BlackRock Investment Management LLC now owns 73,307 shares of the company’s stock valued at $176,000 after buying an additional 36,782 shares during the period. Bank of New York Mellon Corp increased its position in Asterias Biotherapeutics by 55.7% in the second quarter. Bank of New York Mellon Corp now owns 54,406 shares of the company’s stock valued at $131,000 after buying an additional 19,469 shares during the period. Finally, State Street Corp increased its position in Asterias Biotherapeutics by 5.5% in the first quarter. State Street Corp now owns 96,218 shares of the company’s stock valued at $452,000 after buying an additional 5,000 shares during the period.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.